Gamma Knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer

Micaela Motta, Antonella Del Vecchio, Luca Attuati, Piero Picozzi, Lucia Perna, Alberto Franzin, Angelo Bolognesi, Cesare Cozzarini, Riccardo Calandrino, Pietro Mortini, Nadia Di Muzio

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To evaluate clinical and physico-dosimetric variables affecting clinical outcome of patients treated with Gamma Knife radiosurgery (GKRS) for brain metastases from non-small cell lung cancer (NSCLC). Methods and Materials: Between 2001 and 2006, 373 patients (298 men and 75 women, median age 65 years) with brain metastases from NSCLC underwent GKRS. All of them had KPS ≥ 60%, eight or fewer brain metastases, confirmed histopathological diagnosis and recent work-up (3. Median marginal dose was 22.5 Gy at 50% isodose.; median 10 Gy and 12 Gy isodose volumes were 30.8 cm 3 and 15.8 cm 3, respectively. Follow-up with MRI was performed every 3 months. Overall survival data were collected from internal database, telephone interviews, and identifying registries. Results: Mean follow-up after GKRS was 51 months (range, 6 to 96 months); mean overall survival was 14.2 months. Of 373 patients, 29 were alive at time of writing, 104 had died of cerebral progression, and 176 had died of systemic progression. In 64 cases it was not possible to ascertain the cause. Univariate and multivariate analysis were adjusted for the following: RPA class, surgery, WBRT, age, gender, number of lesions, median tumor volume, median peripheral dose, and 10 Gy and 12 Gy volumes. Identified RPA class and overall tumor volume >5 cc were the only two covariates independently predictive of overall survival in patients who died of cerebral progression. Conclusions: Global volume of brain disease should be the main parameter to consider for performing GKRS, which is a first-line therapy for patient in good general condition and controlled systemic disease.

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
Volume81
Issue number4
DOIs
Publication statusPublished - Nov 15 2011

Fingerprint

Radiosurgery
metastasis
Non-Small Cell Lung Carcinoma
lungs
cancer
brain
Neoplasm Metastasis
progressions
Tumor Burden
Survival
Brain
tumors
Therapeutics
dosage
telephones
Brain Diseases
surgery
lesions
Registries
therapy

Keywords

  • Appropriateness criteria
  • Cerebral metastases
  • Gamma Knife
  • Neurocognitive impairment
  • Radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Gamma Knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer. / Motta, Micaela; Del Vecchio, Antonella; Attuati, Luca; Picozzi, Piero; Perna, Lucia; Franzin, Alberto; Bolognesi, Angelo; Cozzarini, Cesare; Calandrino, Riccardo; Mortini, Pietro; Di Muzio, Nadia.

In: International Journal of Radiation Oncology Biology Physics, Vol. 81, No. 4, 15.11.2011.

Research output: Contribution to journalArticle

@article{22e5915f7a6c4d26a25ea1ebfa827235,
title = "Gamma Knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer",
abstract = "Purpose: To evaluate clinical and physico-dosimetric variables affecting clinical outcome of patients treated with Gamma Knife radiosurgery (GKRS) for brain metastases from non-small cell lung cancer (NSCLC). Methods and Materials: Between 2001 and 2006, 373 patients (298 men and 75 women, median age 65 years) with brain metastases from NSCLC underwent GKRS. All of them had KPS ≥ 60{\%}, eight or fewer brain metastases, confirmed histopathological diagnosis and recent work-up (3. Median marginal dose was 22.5 Gy at 50{\%} isodose.; median 10 Gy and 12 Gy isodose volumes were 30.8 cm 3 and 15.8 cm 3, respectively. Follow-up with MRI was performed every 3 months. Overall survival data were collected from internal database, telephone interviews, and identifying registries. Results: Mean follow-up after GKRS was 51 months (range, 6 to 96 months); mean overall survival was 14.2 months. Of 373 patients, 29 were alive at time of writing, 104 had died of cerebral progression, and 176 had died of systemic progression. In 64 cases it was not possible to ascertain the cause. Univariate and multivariate analysis were adjusted for the following: RPA class, surgery, WBRT, age, gender, number of lesions, median tumor volume, median peripheral dose, and 10 Gy and 12 Gy volumes. Identified RPA class and overall tumor volume >5 cc were the only two covariates independently predictive of overall survival in patients who died of cerebral progression. Conclusions: Global volume of brain disease should be the main parameter to consider for performing GKRS, which is a first-line therapy for patient in good general condition and controlled systemic disease.",
keywords = "Appropriateness criteria, Cerebral metastases, Gamma Knife, Neurocognitive impairment, Radiosurgery",
author = "Micaela Motta and {Del Vecchio}, Antonella and Luca Attuati and Piero Picozzi and Lucia Perna and Alberto Franzin and Angelo Bolognesi and Cesare Cozzarini and Riccardo Calandrino and Pietro Mortini and {Di Muzio}, Nadia",
year = "2011",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2011.02.051",
language = "English",
volume = "81",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Gamma Knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer

AU - Motta, Micaela

AU - Del Vecchio, Antonella

AU - Attuati, Luca

AU - Picozzi, Piero

AU - Perna, Lucia

AU - Franzin, Alberto

AU - Bolognesi, Angelo

AU - Cozzarini, Cesare

AU - Calandrino, Riccardo

AU - Mortini, Pietro

AU - Di Muzio, Nadia

PY - 2011/11/15

Y1 - 2011/11/15

N2 - Purpose: To evaluate clinical and physico-dosimetric variables affecting clinical outcome of patients treated with Gamma Knife radiosurgery (GKRS) for brain metastases from non-small cell lung cancer (NSCLC). Methods and Materials: Between 2001 and 2006, 373 patients (298 men and 75 women, median age 65 years) with brain metastases from NSCLC underwent GKRS. All of them had KPS ≥ 60%, eight or fewer brain metastases, confirmed histopathological diagnosis and recent work-up (3. Median marginal dose was 22.5 Gy at 50% isodose.; median 10 Gy and 12 Gy isodose volumes were 30.8 cm 3 and 15.8 cm 3, respectively. Follow-up with MRI was performed every 3 months. Overall survival data were collected from internal database, telephone interviews, and identifying registries. Results: Mean follow-up after GKRS was 51 months (range, 6 to 96 months); mean overall survival was 14.2 months. Of 373 patients, 29 were alive at time of writing, 104 had died of cerebral progression, and 176 had died of systemic progression. In 64 cases it was not possible to ascertain the cause. Univariate and multivariate analysis were adjusted for the following: RPA class, surgery, WBRT, age, gender, number of lesions, median tumor volume, median peripheral dose, and 10 Gy and 12 Gy volumes. Identified RPA class and overall tumor volume >5 cc were the only two covariates independently predictive of overall survival in patients who died of cerebral progression. Conclusions: Global volume of brain disease should be the main parameter to consider for performing GKRS, which is a first-line therapy for patient in good general condition and controlled systemic disease.

AB - Purpose: To evaluate clinical and physico-dosimetric variables affecting clinical outcome of patients treated with Gamma Knife radiosurgery (GKRS) for brain metastases from non-small cell lung cancer (NSCLC). Methods and Materials: Between 2001 and 2006, 373 patients (298 men and 75 women, median age 65 years) with brain metastases from NSCLC underwent GKRS. All of them had KPS ≥ 60%, eight or fewer brain metastases, confirmed histopathological diagnosis and recent work-up (3. Median marginal dose was 22.5 Gy at 50% isodose.; median 10 Gy and 12 Gy isodose volumes were 30.8 cm 3 and 15.8 cm 3, respectively. Follow-up with MRI was performed every 3 months. Overall survival data were collected from internal database, telephone interviews, and identifying registries. Results: Mean follow-up after GKRS was 51 months (range, 6 to 96 months); mean overall survival was 14.2 months. Of 373 patients, 29 were alive at time of writing, 104 had died of cerebral progression, and 176 had died of systemic progression. In 64 cases it was not possible to ascertain the cause. Univariate and multivariate analysis were adjusted for the following: RPA class, surgery, WBRT, age, gender, number of lesions, median tumor volume, median peripheral dose, and 10 Gy and 12 Gy volumes. Identified RPA class and overall tumor volume >5 cc were the only two covariates independently predictive of overall survival in patients who died of cerebral progression. Conclusions: Global volume of brain disease should be the main parameter to consider for performing GKRS, which is a first-line therapy for patient in good general condition and controlled systemic disease.

KW - Appropriateness criteria

KW - Cerebral metastases

KW - Gamma Knife

KW - Neurocognitive impairment

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=80155214687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155214687&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2011.02.051

DO - 10.1016/j.ijrobp.2011.02.051

M3 - Article

VL - 81

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -